Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161719 | 0.81 | PLA2G2A (0.59) | PLA2G2A | |
| SCHEMBL14608292 | 0.75 | ALDH1A1 (0.44) | PLA2G2AMAPTALDH1A1KDM4EJAK2 | |
| SCHEMBL5160140 | 0.73 | PLA2G2A (0.58) | PLA2G2A | |
| SCHEMBL5158958 | 0.70 | PLA2G2A (0.66) | PLA2G2AHTTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL5160095 | 0.67 | PLA2G2A (0.52) | PLA2G2AHTTMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL15426819 | 0.66 | HTT (0.67) | HTTMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL5162627 | 0.65 | ALDH1A1 (0.68) | HTTMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29547089 | 0.65 | HTT (0.54) | HTTMAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2156949 | 0.64 | KDM4E (0.49) | PLA2G2AMAPTALDH1A1KDM4EJAK2 | |
| SCHEMBL10506317 | 0.63 | SMN1; SMN2 (0.60) | HTTMAPTALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358156-B1 | BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2007-02-21 | — | — | EP | disclosed |
| US-6916840-B2 | Spla2 inhibitors | ELI LILLY AND COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040063967-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063967-A1 | Novel spla2 inhibitors | PLA2G12A, SPINT2, PLA2G4A | PLA2G2A 16/4885HTT 4857/4885MAPT 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.